FDA’s U-turn on Regenxbio’s gene therapy exposes systemic gaps in rare disease drug approval and patent monopolies
Original framing: “STAT+: FDA reverses course on Regenxbio’s childhood gene therapy after rejection” — STAT News
The FDA’s reversal echoes historical patterns of regulatory agencies bowing to corporate pressure, such as the 2016 EpiPen scandal or the opioid epidemic’s regulatory failures. Rare disease treatments have long been sidelined until public outrage or legal threats force action, as seen with cystic fibrosis drugs like Kalydeco. The gene therapy industry’s boom mirrors past biotech bubbles (e.g., antisense therapies in the 1990s), where hype outpaced evidence, leaving patients in limbo.
The FDA’s reversal on Regenxbio’s gene therapy for Hunter syndrome exposes a healthcare system where regulatory whiplash is less about science than about power: patent monopolies, patient advocacy capture, and the FDA’s risk-averse culture all collide in a high-stakes game where ‘rare’ diseases are treated as market failures rather than moral imperatives.
Historically, this mirrors past biotech booms (e.g., antisense therapies) where hype outpaced evidence, leaving patients in limbo—yet the current reversal suggests a fragile shift toward adaptive regulation, driven by patient pressure and emerging data. Cross-culturally, the Western biomedical model’s focus on gene editing contrasts sharply with Indigenous and holistic traditions that frame genetic difference as part of a communal tapestry, revealing how ‘cure’ is a culturally constructed goal. The trickster’s hand is evident in how Hermes-like maneuvering turns regulatory gaps into profit, while marginalized voices—especially from the Global South—remain unheard. The path forward requires dismantling patent-driven incentives, centering public funding and open-source collaboration, and embedding cultural humility into regulatory processes to ensure therapies serve humanity, not just markets.